The molecular characterization of MDS adds further prognostic information with mutations involving TP53, EZH2, ETV6, RUNX1, and ASXL1 associated with decreased overall survival and higher risk of AML transformation (5, 6). The gene discussed is TP53; the disease is acute myeloid leukemia.